These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30152116)

  • 1. Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center.
    Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Ruiz P; Vianna R; Burke GW
    Clin Transplant; 2018 Oct; 32(10):e13392. PubMed ID: 30152116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.
    Wu K; Budde K; Schmidt D; Neumayer HH; Lehner L; Bamoulid J; Rudolph B
    Clin Transplant; 2016 Feb; 30(2):105-17. PubMed ID: 26448478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.
    Orandi BJ; Alachkar N; Kraus ES; Naqvi F; Lonze BE; Lees L; Van Arendonk KJ; Wickliffe C; Bagnasco SM; Zachary AA; Segev DL; Montgomery RA
    Am J Transplant; 2016 Jan; 16(1):213-20. PubMed ID: 26317487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Older kidney transplant patients experience less antibody-mediated rejection: a retrospective study of patients with mild to moderate sensitization.
    Scalea JR; Redfield RR; Muth BL; Mohamed M; Wilson NA; Ellis TM; Kaufman DB; Djamali A
    Clin Transplant; 2015 Dec; 29(12):1090-7. PubMed ID: 26361077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
    Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
    Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection.
    Torres IB; Salcedo M; Moreso F; Sellarés J; Castellá E; Azancot MA; Perelló M; Cantarell C; Serón D
    Clin Transplant; 2014 Oct; 28(10):1148-54. PubMed ID: 25103874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.
    Hellemans R; Hazzan M; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Noël C; Abramowicz D
    Am J Transplant; 2015 Jul; 15(7):1923-32. PubMed ID: 25707875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function.
    Ravindra KV; Sanoff S; Vikraman D; Zaaroura A; Nanavati A; Sudan D; Irish W
    Am J Transplant; 2019 Mar; 19(3):781-789. PubMed ID: 30171800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study.
    Alkadi MM; Kim J; Aull MJ; Schwartz JE; Lee JR; Watkins A; Lee JB; Dadhania DM; Seshan SV; Serur D; Kapur S; Suthanthiran M; Hartono C; Muthukumar T
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28921709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic patterns and treatment of transplant glomerulopathy: A retrospective analysis.
    Abreu R; Carvalho F; Viana H; Mesquita I; Possante M; Aires I; Caeiro F; Silva C; Cotovio P; Ferreira A; Remédio F; Nolasco F
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28135784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipients.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Hanson L; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Barba LJ; Lopez A; Rivas J; Ruiz P; Vianna R; Burke GW
    Clin Transplant; 2015 Apr; 29(4):301-10. PubMed ID: 25581205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay.
    Nin M; Coitiño R; Kurdian M; Orihuela L; Astesiano R; Garau M; López D; Rievas G; Rodriguez I; González-Martínez F; Noboa O
    Transplant Proc; 2016 Mar; 48(2):612-5. PubMed ID: 27110014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.